	IPE	
O	Please type a plus sign (+) inside this	s box →
	0)	ر ب

Signature

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/21 (08-00)

B 0 4	2002 A	enenwyk Reduction Act o	of 1995 pc	nercone are		t and Tra	Approval for use through 10/31/2002. OMB ademark Office; U.S. DEPARTMENT OF Committee unless it displays a valid OMB control of the control o	OMMERC	
Under the Paperwork Reduction Act of 1995, no persons are					Application Number		09/667,380		
TRANSMITTAL					Filing Date		September 22, 2000	운	
FORM			First Named Invento	or	Donoho	CEA			
					Group Art Unit		1653	CENTER	
(1	(to be used for all correspondence after initial filing)				Examiner Name		R. Mitra	1600	
	Total Number of Pages in This Submission 4			Attorney Docket Num	ber	LEX-0042-USA	/290		
			EN	CLOSUR	RES (check all that ap	pply)		0	
	Fee Transmi	ittal Form		Assignme (for an Ap	nt Papers		After Allowance Communication to Group		
	Fee A	ttached		Drawing(s	)		Appeal Communication to Board of Appeals and Interferences	!	
	Amendment	/ Reply		Licensing-	related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	)	
	After F	Final		Petition			Proprietary Information		
	Extension of Time Request  Express Abandonment Request  Te		Petition to Convert to a Provisional Application				Status Letter		
			Power of Attorney, Revocation Change of Correspondence Address		X	urn postcard; sponse to Notice to Comply; urn copy of Notice to Comply; ified Statement;			
			Terminal [						
			Request for Refund Veri		Verifi				
	Certified Copy of Priority Document(s)		CD, Number of CD(s)		Sequ	ence Listing on diskette			
	Response to Missing Parts/ Incomplete Application								
		onse to Missing Parts 37 CFR 1.52 or 1.53	•						
		616	NATUE	E OF AD	DUCANT ATTORNEY	OD 46	NAT.		
Firm		SIG	INAIUF	IE UF AP	PLICANT, ATTORNEY,	UH AC	ZEN I		
or Lance K. Ishimoto Reg. No. 41,8 Individual name Lexicon Genetics Incorporated					,866				
Signature Lance K. Schenwo ay Da			lewil W. Jabler	DAV	ND W HBLER NY 41,071				
Date January 16, 2002		2							
CERTIFICATE OF MAILING									
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class									
mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: January 16, 2002									
Typed or printed name   Michelle Klein									

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

Date

January 16, 2002

•				<u> </u>				
101	PE	Application No.	Applicant(s)	30 HG				
/ 550 A	4 2002 Notice to Comply.	09/667380	Donoho et al.					
res u 교		Examiner	Art Unit	O 7				
FEFT & PRAI		Rita Mitra, Ph. D.	1653	<b>≒</b> ~				
RAI	CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE							
	DISCLOSURES	OLIVOL AND/OR AMINO	AOID OEGOEI	8				
	Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).  The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):  1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).  2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).							
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).							
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/o 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."							
	5. The computer readable form that he and/or unreadable as indicated on the readable form must be submitted as re	attached CRF Diskette Problen	n has been found t n Report. A Substi	o be damaged tute computer				
	6. The paper copy of the "Sequence L "Sequence Listing" as required by 37	isting" is not the same as the co C.F.R. 1.821(e).	mputer readable fr	om of the				
	☐ 7. Other:							
	An initial or substitute paper copy of the into the specification.	ne "Sequence Listing", as well a	s an amendment d	irecting its entry				
	A statement that the content of the applicable, include no new matter, as rec 1.825(d).	paper and computer readable quired by 37 C.F.R. 1.821(e) or	copies are the sa 1.821(f) or 1.821(a	ame and, where g) or 1.825(b) or				
	For questions regarding compliance	e to these requirements, p	lease contact:					
	For Rules Interpretation, call (703)	308-4216						

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY